Keyword: Janssen Biotech

Johnson & Johnson has expanded its Cork Co., Ireland biologics site with a $350 million facility, adding 200 jobs in the process.

J&J enlisted British celebrity home stylist Laurence Llewelyn-Bowen to raise awareness of blood cancer and its symptoms this month.

ICER has ruled that neither Novartis' $88,500 MS drug Mayzent nor J&J's $32,400 depression spray Spravato is cost effective.

J&J's med should have faced generics years ago, a lawsuit claims, but J&J used underhanded tactics to keep cheaper copycats at bay.

Gilead has reaped billions of dollars in sales from "unlawfully monopolized" HIV drugs, patients and activists say in a new class action lawsuit.

Patients with treatment-resistant depression have a new option in J&J's Spravato, but the cost watchdogs at ICER say it's not cost-effective.

J&J’s commissioned film about the early days of the AIDS epidemic is set to attract a wider audience, thanks to a Verizon Media distribution deal.

Chinese CDMO GenScript Biotech has started construction on a production facility to specialize in plasmids and viruses manufacturing.

Janssen's workers at a plant in California will be let go over the next three years, staring with nearly 50 being whacked next week.

Johnson & Johnson is the first pharma to announce it will put drug list prices directly in TV ads, self-regulating ahead of a proposed regulation.